ArticleNanomedicine (London, England)2025
Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe development of multifunctional nanoplatforms capable of simultaneous therapeutic and diagnostic applications is a growing focus in biomedical research. METHODS/MATERIALS: In this study, silver sulfide - silver nanoparticles coated with bovine serum albumin (Ag₂S-Ag@BSA) were synthesized via a one-step biomineralization method at room temperature. Methotrexate (MTX), a chemotherapeutic agent, was chemically conjugated to the nanoparticles to enhance targeted anticancer activity. Comprehensive characterization using FTIR, UV-Vis, XRD, TEM, and DLS confirmed successful synthesis.
resultsTEM analysis revealed spherical nanoparticles with an average diameter of 12.02 nm, while DLS indicated a hydrodynamic size of 40 nm, a polydispersity index of 0.20, and a zeta potential of -24 mV, reflecting good stability. Drug release studies demonstrated enzyme-responsive behavior, with significantly increased MTX release in the presence of proteinase K, simulating intracellular protease activity.
conclusionThese results suggest that Ag₂S-Ag@BSA-MTX nanoparticles offer a promising multifunctional approach for cancer theranostics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.